Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: A new link between obesity and heart disease

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Valéria Lamounier-Zepter - , Department of Internal Medicine 3 (Author)
  • Christiane Look - , Department of Internal Medicine 3 (Author)
  • Julio Alvarez - , Institute of Cardiology (Author)
  • Torsten Christ - , Leibniz Institute for Molecular Pharmacology (Author)
  • Ursula Ravens - , Leibniz Institute for Molecular Pharmacology (Author)
  • Wolf Hagen Schunck - , Max Delbrück Center for Molecular Medicine (MDC) (Author)
  • Monika Ehrhart-Bornstein - , Department of Internal Medicine 3 (Author)
  • Stefan R. Bornstein - , Department of Internal Medicine III (Author)
  • Ingo Morano - , Max Delbrück Center for Molecular Medicine (MDC), Charité – Universitätsmedizin Berlin (Author)

Abstract

Rationale: Adipocyte fatty acid-binding protein (FABP4) is a member of the intracellular lipid-binding protein family and is predominantly expressed in adipose tissue. Emerging evidence suggests that FABP4 plays a role in some aspects of the metabolic syndrome including the development of type 2 diabetes and atherosclerosis. We have recently reported that secretory products from human adipocytes directly and acutely depressed cardiac contractile function. Objective: The purpose of this study was to identify this adipocyte-derived cardiodepressant factor. Methods and results: Through mass spectrometry and immunoblotting, we have identified this cardiodepressant factor as FABP4. FABP4 represents 1.8% to 8.1% of total protein secreted by adipocytes in extracellular medium. FABP4 acutely depressed shortening amplitude as well as intracellular systolic peak Ca2+ in a dose-dependent manner in isolated rat cardiomyocytes. Heart-specific FABP isoform (FABP3) revealed a similar cardiodepressant effect. The N-terminal amino acids 1 to 20 of FABP4 could be identified as the most effective cardiodepressive domain. We could exclude any effect of FABP4 on action potential duration and L-type Ca2+ current, suggesting a reduced excitation-contraction gain caused by FABP4 as the main inhibitory mechanism. CONCLUSION:: We conclude that the release of FABP4 from adipocytes may be involved in the development of cardiac contractile dysfunction of obese subjects.

Details

Original languageEnglish
Pages (from-to)326-334
Number of pages9
JournalCirculation research
Volume105
Issue number4
Publication statusPublished - 14 Aug 2009
Peer-reviewedYes

External IDs

PubMed 19608978

Keywords

Sustainable Development Goals

Keywords

  • Adipocytes, FABP4, Heart failure, Metabolic syndrome